CAR T-cell therapy explored as potential option for advanced renal cell carcinoma
Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.
FDA approves niraparib/abiraterone tablet for BRCA-positive mCRPC
The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.
Dr. Xu discusses treatment selection across therapy lines in renal cell carcinoma
“Now in 2023, it’s really a question of how to apply these agents and which combinations to use in the first line,” said Vincent (Wenxin) Xu, MD.
FDA approval sought for niraparib/abiraterone tablet for BRCA+ mCRPC
The application is supported by findings from the phase 3 MAGNITUDE study.
Exploratory analysis shows no OS benefit with atezolizumab monotherapy in advanced urothelial cancer
An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Testicular cancer patient has complete response to CAR T-cell therapy
The patient had previously received 6 lines of chemotherapy treatment and was still in an ongoing complete response at the time of the study analysis.
Study identifies biomarkers of enhanced nivolumab/ipilimumab efficacy in renal cell carcinoma
The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was linked to an increased response rate and prolonged progression-free survival.
N-803 plus BCG yields prolonged complete responses and DFS in NMIBC
At a median follow-up of 20.7 months in patients with papillary disease (n = 77), the median DFS was 23.6 months.
Dr. Gomella explains the evolving precision medicine paradigm in prostate cancer
The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.
No OS benefit at 1-year mark with upfront avelumab in cisplatin-ineligible urothelial cancer
Despite missing the primary end point, avelumab did demonstrate notable clinical activity and a favorable safety profile in the phase 2 ARIES trial.
Niraparib and abiraterone combo significantly delays mCRPC progression
Findings from the phase 3 MAGNITUDE trial showed that adding niraparib to abiraterone acetate significantly extended radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Pembrolizumab plus cabozantinib highly active in metastatic kidney cancer
Nearly two-thirds of patients with metastatic renal cell carcinoma responded to the combination.
2 Clarke Drive Cranbury, NJ 08512